The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.
 
Amy Jo Chien
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Merck (Inst); Puma Biotechnology (Inst); Seagen (Inst)
 
Amelia S Gliwa
No Relationships to Disclose
 
Siti Rahmaputri
No Relationships to Disclose
 
Heidi F Dittrich
No Relationships to Disclose
 
Melanie Catherine Majure
No Relationships to Disclose
 
Hope S. Rugo
Consulting or Advisory Role - Celltrion; Ionis Pharmaceuticals
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Honoraria - Agendia; Genentech (I); Pfizer (I)
Speakers' Bureau - Agendia; Genentech (I); Pfizer (I)
Research Funding - Celldex (Inst); Genentech (Inst); Lilly (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
 
Pamela N. Munster
Leadership - Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics
Honoraria - AtlasMedx; Celgene; CStone Pharmaceuticals; Epigene; McVeigh; Prometheus (I); Xynomic Pharma (Inst)
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
 
John W. Park
Stock and Other Ownership Interests - Merrimack
Consulting or Advisory Role - Genentech
Speakers' Bureau - Genentech; Pfizer
Patents, Royalties, Other Intellectual Property - University of California, San Francisco
Expert Testimony - Genentech
 
Mark M. Moasser
No Relationships to Disclose
 
Mehrdad Matloubian
Consulting or Advisory Role - Virtuoso Therapeutics
 
Tasha Lea
No Relationships to Disclose
 
Julia Rohrberg
No Relationships to Disclose
 
Gregor Krings
Honoraria - Novartis
Speakers' Bureau - Novartis
 
Andrei Goga
No Relationships to Disclose